Results 21 to 30 of about 255,027 (296)

Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer

Cellular & Molecular Immunology, 2020
Vγ9Vδ2 T cells are promising candidates for cellular tumor immunotherapy. Due to their HLA-independent mode of action, allogeneic Vγ9Vδ2 T cells can be considered for clinical application. To apply allogeneic Vγ9Vδ2 T cells in adoptive immunotherapy, the
Yan Xu, Zheng Xiang, M. Alnaggar, Léonce Kouakanou, Jiawei Li, Junyi He, Jiashuang Yang, Y. Hu, Yan Chen, Li Lin, Jianlei Hao, Jingxia Li, Jibing Chen, Man Li, Qingling Wu, C. Peters, Qinghua Zhou, Jianshuang Li, Yingqing Liang, Xiaohua Wang, B. Han, M. Ma, D. Kabelitz, Kecheng Xu, W. Tu, Yangzhe Wu, Z. Yin   +26 more
semanticscholar   +1 more source

IFNγ, and to a Lesser Extent TNFα, Provokes a Sustained Endothelial Costimulatory Phenotype

Frontiers in Immunology, 2021
BackgroundVascular endothelial cells (EC) are critical for regulation of local immune responses, through coordination of leukocyte recruitment from the blood and egress into the tissue.
Nicole M. Valenzuela
doaj   +1 more source

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts

CNS Oncology, 2018
Aim: ERC1671 is an allogeneic/autologous therapeutic glioblastoma (GBM) vaccine – composed of whole, inactivated tumor cells mixed with tumor cell lysates derived from the patient and three GBM donors.
Daniela A Bota, Jinah Chung, Manisha Dandekar, Jose A Carrillo, Xiao-Tang Kong, Beverly D Fu, Frank PK Hsu, Axel H Schönthal, Florence M Hofman, Thomas C Chen, Raphael Zidovetzki, Chrystel Pretto, Ankie Strik, Virgil EJC Schijns, Apostolos Stathopoulos   +14 more
doaj   +1 more source

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Oncology, 2020
Relapse is the main cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Ahmad I. Antar, Ahmad I. Antar, Zaher K. Otrock, Iman Abou Dalle, Jean El-Cheikh, Ali Bazarbachi   +5 more
doaj   +1 more source

Interactions Between Allogeneic Mesenchymal Stromal Cells and the Recipient Immune System: A Comparative Review With Relevance to Equine Outcomes

Frontiers in Veterinary Science, 2021
Despite significant immunosuppressive activity, allogeneic mesenchymal stromal cells (MSCs) carry an inherent risk of immune rejection when transferred into a recipient.
J. Lacy Kamm, Christopher B. Riley, Natalie Parlane, Erica K Gee, C. Wayne McIlwraith   +4 more
doaj   +1 more source

Physiological problems in patients undergoing autologous and allogeneic hematopoietic stem cell transplantation

Asia-Pacific Journal of Oncology Nursing, 2014
Objective: Stem cell transplantation is usually performed in an effort to extend the patient′s life span and to improve their quality of life. This study was conducted to determine the postoperative physiological effects experienced by patients who had ...
Sevgisun Kapucu, Yasemin Karacan
doaj   +1 more source

Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy

Cancer immunology research, 2020
Antitumor T-cell grafts with HLA class I, HLA class II, and TCR molecules concurrently ablated evade allogeneic T-cell responses. These cells can be used as a universal T-cell source for adoptive cancer immunotherapy.
Yuki Kagoya, Tingxi Guo, B. Yeung, Kayoko Saso, M. Anczurowski, Chung-Hsi Wang, K. Murata, Kenji Sugata, H. Saijo, Yukiko Matsunaga, Y. Ohashi, M. Butler, N. Hirano   +12 more
semanticscholar   +1 more source

Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning?

Frontiers in Immunology, 2017
Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppressive/anti-inflammatory ...
Paul Lohan, Oliver Treacy, Oliver Treacy, Matthew D. Griffin, Matthew D. Griffin, Thomas Ritter, Thomas Ritter, Aideen E. Ryan, Aideen E. Ryan   +8 more
doaj   +1 more source

HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells

Nature Biotechnology, 2017
Polymorphisms in the human leukocyte antigen (HLA) class I genes can cause the rejection of pluripotent stem cell (PSC)-derived products in allogeneic recipients.
Germán G. Gornalusse, R. Hirata, S. Funk, Laura Riolobos, V. Lopes, Gabriel Manske, D. Prunkard, A. Colunga, L. Hanafi, D. Clegg, C. Turtle, D. Russell   +11 more
semanticscholar   +1 more source

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

Nature Medicine
There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen ...
David Marin, Ye Li, R. Başar, H. Rafei, May Daher, J. Dou, Vakul Mohanty, Merve Dede, Y. Nieto, N. Uprety, S. Acharya, E. Liu, Jeffrey Wilson, P. Banerjee, H. Macapinlac, C. Ganesh, P. Thall, R. Bassett, Mariam Ammari, Sheetal S Rao, K. Cao, M. Shanley, Mecit Kaplan, C. Hosing, P. Kebriaei, L. Nastoupil, C. Flowers, S. M. Moseley, Paul Lin, Sonny Ang, U. Popat, M. Qazilbash, R. Champlin, Ken Chen, E. Shpall, K. Rezvani   +35 more
semanticscholar   +1 more source